local_hospital

Hospital Universitario De Jaen

Address
lock Available on a paid plan

Oncology and Breast Cancer Research

At Hospital Universitario De Jaen, a major share of the clinical trial portfolio focuses on neoplasms, especially breast cancer. Research includes early-stage, locally advanced, metastatic, and high-risk disease, with studies designed to improve treatment effectiveness, reduce recurrence, and refine care after surgery or neoadjuvant therapy.

  • Hormone receptor-positive and HER2-negative breast cancer
  • HER2-positive and triple-negative breast cancer
  • Metastatic and high-risk early breast cancer
  • Testing new combinations and supportive strategies to improve outcomes

This work reflects a strong focus on modern oncology care, with trials aimed at better disease control and more personalized treatment choices.

Lung Cancer and Thoracic Oncology

Another prominent area is respiratory tract disease research, particularly non-small cell lung cancer and small cell lung cancer. The trials explore treatment options for advanced, metastatic, and resectable disease, including studies that assess whether newer therapies can improve survival, delay progression, or support care after surgery.

  • Advanced and metastatic non-small cell lung cancer
  • Small cell lung cancer and limited-stage disease
  • EGFR-, RET-, KRAS-, and PD-L1-related lung cancer research
  • Evaluating new targeted and immunotherapy-based approaches

This area shows active investigation into more precise and effective treatment strategies for complex lung cancer cases.

Gynecologic, Hepatic, and Other Solid Tumors

The site also studies a broad range of other solid tumors, including ovarian cancer, endometrial cancer, head and neck squamous cell carcinoma, hepatocellular carcinoma, and prostate cancer. These trials often aim to improve disease control in advanced or recurrent settings and to test whether new regimens can offer better outcomes for patients with limited options.

  • Ovarian, endometrial, and fallopian tube cancers
  • Head and neck cancer and hepatocellular carcinoma
  • Metastatic and unresectable solid tumors
  • Assessing new therapies for harder-to-treat cancers

The research portfolio highlights a broad oncology focus beyond breast and lung cancer, with attention to both tumor control and long-term benefit.

Cardiovascular and Metabolic Disease Studies

Clinical trials at the site also address cardiovascular diseases and nutritional and metabolic diseases. Research includes conditions such as atherosclerotic cardiovascular disease, hypertension, spontaneous coronary artery dissection, transthyretin amyloid cardiomyopathy, and type 2 diabetes, with studies focused on improving prevention and treatment.

  • Atherosclerotic cardiovascular disease and elevated lipoprotein(a)
  • Hypertension, heart failure, and coronary disorders
  • Type 2 diabetes and severe hypertriglyceridemia
  • Testing therapies that may reduce events and improve long-term health

This research supports better management of chronic cardiometabolic conditions that affect many adults.

Infections, Immune, and Skin-Related Conditions

The trial landscape at Hospital Universitario De Jaen includes studies in bacterial infections and mycoses, immune system diseases, and skin and connective tissue diseases. Examples include bacteremia, septic shock, allergic rhinitis with asthma, and atopic dermatitis, with research aimed at improving treatment effectiveness, safety, and symptom control.

  • Bloodstream infections and septic shock
  • Allergic and immune-mediated conditions
  • Atopic dermatitis and related skin disease
  • Comparing treatments to improve outcomes and reduce side effects

These studies show a balanced interest in both acute infectious disease care and longer-term immune-mediated conditions.

Site Overview

assignment
134
connected trials
corporate_fare
69
sponsors
science
229
IMPs

Activity Indicator

Last 6 months

13
Trials started
-19% vs previous period.
16
Trials started 6–12 months ago
134
Total trials linked
Highly Active
trending_downDeclining-19%
3
5
1
4
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status

Top 2 of 13 therapeutic areas and 15 of 229 IMPs, ranked by number of trials.

lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years

Top 40 of 222 compounds, ranked by number of trials.

lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
62
Sponsors (total)
69
Active sponsors
43

Sponsor Network

Top 43 by active trials.

lock +42 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

lock +26 more on a paid plan

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 567 other sites in Spain

description
Trial volume
134
Outperforms 92% of sites
public
Therapeutic diversity
13areas
Outperforms 88% of sites
groups
Sponsor diversity
69sponsors
Outperforms 91% of sites

Therapeutic Area Benchmark — Spain

Select a therapeutic area to compare against other sites in Spain.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Spain

Market Share

Country: Spain

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Hospital Universitario De Jaen

lock Showing 1 of 134 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
A Comparative Study of ABP 234 and Pembrolizumab in Patients with Advanced or Metastatic Non-Squamous Non-Small Cell Lung CancerAmgen Inc.Phase IRecruitingOct 2024

IMP list

lock Showing 1 of 229 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Pembrolizumab20Unknown2018-08-242026-06-11

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.